STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #1418 by analyst upside · 2026-06-27
COLL
Collegium Pharmaceutical, Inc.
Healthcare · Market Cap $1B · P/E 17.8x
ANALYST PRICE TARGET
+48.5%
implied upside to consensus target
Current Price $36.59
Consensus Target $54.33
Bull Target $60.0
Bear Target $45.0
Analysts Covering 6
ANALYST CONSENSUS — BUY
Strong Buy
2
Buy
3
Hold
1
Sell
0
52-Week Low $29.19
52-Week High $50.79
YTD Return -19.6%
FUNDAMENTALS
Market Cap $1B
P/E Ratio (TTM) 17.8x
Forward P/E 4.8x
EPS (TTM) $2.06
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $796M
Profit Margin 9.4%
52-WEEK RANGE
52-Week Low $29.19
52-Week High $50.79
Current Price $36.59
Bear Target $45.0
Bull Target $60.0
● Now $36.59 ● Target $54.33
TRADING DATA
Avg Volume 456K
YTD Return -19.6%
Analyst Count 6
Consensus Buy
Upside to Target +48.5%
Last Updated 2026-06-27

ANALYST SUMMARY

Collegium Pharmaceutical, Inc. (COLL) is currently trading at $36.59 with a Wall Street consensus price target of $54.33, implying potential upside of 48.5% over the next 12 months. 6 analysts currently cover COLL, with a consensus rating of Buy — 83% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $60.0, while the most cautious has a target of $45.0.

COLL operates in the Healthcare sector with a market capitalisation of $1B. The stock is down 19.6% year-to-date and is currently trading near the lower end of its 52-week range of $29.19 – $50.79.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for COLL, with each firm's 90-day track record across all stocks we track. See full firm rankings →

HC Wainwright & Co. reit
Buy → Buy 2026-03-20 31% win rate (48 calls)
Needham reit
Buy → Buy 2026-03-19 20% win rate (5 calls)
Needham — Reiterated
Buy → Buy 2026-02-26 20% win rate (5 calls)
Barclays — Reiterated
Overweight → Overweight 2026-01-09 Building track record
HC Wainwright & Co. reit
Buy → Buy 2026-01-09 31% win rate (48 calls)
Needham — Reiterated
Buy → Buy 2026-01-08 20% win rate (5 calls)
Barclays ● Initiated
Overweight 2025-12-09 Building track record
Truist Securities — Reiterated
Buy → Buy 2025-11-07 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
59
out of 100
Coverage depth
15/30
Consensus clarity
22/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call — not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →